

AMENDMENTS TO THE CLAIMS

The following list of claims replaces any prior claims in the application:

1. (Currently amended) An isolated nucleic acid molecule ~~comprising the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and/or 11 or a complement thereof, or a portion thereof~~ consisting essentially of the nucleotide sequence of SEQ ID NO:1 and/or a complement of SEQ ID NO:1, or at least 10 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1 and/or a complement of said contiguous nucleotides.
2. (Original) The nucleic acid molecule of claim 1 wherein said nucleic acid molecule is double-stranded.
3. (Original) The nucleic acid molecule of claim 2 wherein said nucleic acid molecule is a RNA.
4. (Original) An isolated nucleic acid molecule which hybridizes under stringent conditions to the nucleic acid molecule of claim 1 or a complement thereof.
5. (Withdrawn) An isolated polypeptide encoded by the nucleic acid molecule of claim 1.
6. (Withdrawn) An isolated antibody or an antigen-binding fragment thereof which immunospecifically binds the polypeptide of claim 5.
7. (Currently amended) A vector comprising a nucleic acid molecule ~~comprising the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and/or 11, or a complement thereof~~ of claim 1.
8. (Currently amended) ~~[[A]]~~ An isolated host cell containing the vector of claim 7.

9. (Original) An immunogenic formulation comprising an immunogenically effective amount of the nucleic acid molecule of claim 1, and a pharmaceutically acceptable carrier.

10. (Withdrawn) An immunogenic formulation comprising an immunogenically effective amount of the polypeptide of claim 5, and a pharmaceutically acceptable carrier.

11. (Cancelled).

12. (Withdrawn) A vaccine formulation comprising a therapeutically or prophylactically effective amount of the polypeptide of claim 5, and a pharmaceutically acceptable carrier.

13. (Original) A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the nucleic acid molecule of claim 1.

14. (Withdrawn) A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the antibody of claim 6.

15. (Cancelled).

16. (Cancelled).

17. (Cancelled).

18. (Cancelled).

19. (Cancelled).

20. (New) An isolated nucleic acid molecule consisting essentially of the nucleotide sequence of SEQ ID NO:4 and/or a complement of SEQ ID NO:4, or at least

10 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:4 and/or a complement of said contiguous nucleotides.

21. (New) The nucleic acid molecule of claim 20 wherein said nucleic acid molecule is double-stranded.

22. (New) The nucleic acid molecule of claim 21 wherein said nucleic acid molecule is a RNA.

23. (New) An isolated nucleic acid molecule which hybridizes under stringent conditions to the nucleic acid molecule of claim 20 or a complement thereof.

24. (New) A vector comprising a nucleic acid molecule of claim 20.

25. (New) An isolated host cell containing the vector of claim 24.

26. (New) An immunogenic formulation comprising an immunogenically effective amount of the nucleic acid molecule of claim 20, and a pharmaceutically acceptable carrier.

27. (New) A vaccine formulation comprising a therapeutically or prophylactically effective amount of the nucleic acid molecule of claim 20, and a pharmaceutically acceptable carrier.

28. (New) A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the nucleic acid molecule of claim 20.

29. (New) A kit comprising a container containing the immunogenic formulation of claim 26.

30. (New) A kit comprising a container containing the vaccine formulation of claim 27.

31. (New) A kit comprising a container containing the pharmaceutical composition of claim 28.

32. (New) A method for preventing or treating SARS comprising administering to a subject in need thereof a therapeutically or prophylactically effective amount of the nucleic acid molecule consisting essentially of the nucleotide sequence of SEQ ID NO:4 and/or a complement of SEQ ID NO:4, or at least 10 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:4 and/or a complement of said contiguous nucleotides.

33. (New) A method for inhibiting SARS viral infection or replication in a cell comprising administering to the cell an effective amount of the nucleic acid molecule consisting essentially of the nucleotide sequence of SEQ ID NO:4 and/or a complement of SEQ ID NO:4, or at least 10 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:4 and/or a complement of said contiguous nucleotides.